The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.
|Videos|April 12, 2022
A Team Approach to Atopic Dermatitis Treatment
Author(s)Colleen Hall
Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, California, discusses the importance of recognizing children with more severe atopic disease and a team approach to treatment.
Advertisement
In this video, Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, California, discusses the importance of recognizing children with more severe atopic disease and a team approach to treatment.
He was one of the featured speakers at the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference being held from April 9 to 11 in Baltimore, Maryland.
Advertisement
Related to this article
Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
3
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
4
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
5